<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>off-label treatment &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/off-label-treatment/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 13:15:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>off-label treatment &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Intravenous Esketamine Acts Faster, but Subcutaneous Route Matches Final Outcomes in Treatment-Resistant Depression</title>
		<link>https://bioengineer.org/intravenous-esketamine-acts-faster-but-subcutaneous-route-matches-final-outcomes-in-treatment-resistant-depression/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 13:15:25 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[BDI-II]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[dissociation]]></category>
		<category><![CDATA[esketamine]]></category>
		<category><![CDATA[intravenous administration]]></category>
		<category><![CDATA[ketamine]]></category>
		<category><![CDATA[NMDA receptor antagonism]]></category>
		<category><![CDATA[off-label treatment]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[subcutaneous administration]]></category>
		<category><![CDATA[treatment-resistant depression]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=427511</guid>

					<description><![CDATA[A multicenter Brazilian study finds intravenous esketamine produced faster antidepressant response in treatment-resistant depression, while a longer subcutaneous protocol achieved comparable final outcomes with far less dissociation.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">427511</post-id>	</item>
	</channel>
</rss>
